Myocarditis

Progress in Cardiovascular Diseases

Volumn 52, Issue 4, 2010, Pages 274-288

  Blauwet, Lori A ^a   Cooper, Leslie T ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dilated cardiomyopathy; Endomyocardial biopsy; Heart failure; Myocarditis

Indexed keywords

AMLODIPINE; ANTHRACYCLINE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; AZATHIOPRINE; BETA INTERFERON; BISOPROLOL; CARVEDILOL; COCAINE; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYCLOSPORIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IMMUNOGLOBULIN; INOTROPIC AGENT; METOPROLOL SUCCINATE; NEUROLEPTIC AGENT; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; RECOMBINANT INTERFERON; RIBAVIRIN; VASODILATOR AGENT;

ARTICLE; ASSISTED CIRCULATION; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CARDIOMYOPATHY; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART TRANSPLANTATION; HUMAN; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LABORATORY DIAGNOSIS; LOW DRUG DOSE; MYOCARDITIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROGNOSIS; PROTOZOAL INFECTION; SENSITIVITY AND SPECIFICITY; SYSTEMIC DISEASE; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VIRUS ENTRY; VIRUS GENOME; VIRUS MYOCARDITIS;

ADULT; AGE FACTORS; ANIMALS; CARDIOMYOPATHY, DILATED; CHILD, PRESCHOOL; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MYOCARDITIS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73049091576     PISSN: 00330620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcad.2009.11.006     Document Type: Article

References (188)

1. Chow L.H., Radio S.J., Sears T.D., et al. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol 14 (1989) 915-920
2. Baughman K.L. Diagnosis of myocarditis: death of Dallas criteria. Circulation 113 (2006) 593-595
3. Herskowitz A., Ahmed-Ansari A., Neumann D.A., et al. Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. J Am Coll Cardiol 15 (1990) 624-632
4. Maisch B., Portig I., Ristic A., et al. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus. A status report. Herz 25 (2000) 200-209
5. Kindermann I., Kindermann M., Kandolf R., et al. Predictors of outcome in patients with suspected myocarditis. Circulation 118 (2008) 639-648
6. Friedrich M.G., Sechtem U., Schulz-Menger J., et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 53 (2009) 1475-1487
7. Mahrholdt H., Goedecke C., Wagner A., et al. Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation 109 (2004) 1250-1258
8. Gutberlet M., Spors B., Thoma T., et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology 246 (2008) 401-409
9. Cooper L.T., Baughman K.L., Feldman A.M., et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116 (2007) 2216-2233
10. Wakafuji S., and Okada R. Twenty year autopsy statistics of myocarditis incidence in Japan. Jpn Circ J 50 (1986) 1288-1293
11. Carniel E., Sinagra G., Bussani R., et al. Fatal myocarditis: morphologic and clinical features. Ital Heart J 5 (2004) 702-706
12. Kyto V., Saraste A., Voipio-Pulkki L.M., et al. Incidence of fatal myocarditis: a population-based study in Finland. Am J Epidemiol 165 (2007) 570-574
13. Gravanis M.B., and Sternby N.H. Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch Pathol Lab Med 115 (1991) 390-392
14. Doolan A., Langlois N., and Semsarian C. Causes of sudden cardiac death in young Australians. Med J Aust 180 (2004) 110-112
15. Hahn E.A., Hartz V.L., Moon T.E., et al. The Myocarditis Treatment Trial: design, methods and patients enrollment. Eur Heart J 16 Suppl O (1995) 162-167
16. Kuhl U., Pauschinger M., Noutsias M., et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 111 (2005) 887-893
17. Mason J.W., O'Connell J.B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333 (1995) 269-275
18. Caforio A.L., Calabrese F., Angelini A., et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 28 (2007) 1326-1333
19. Magnani J.W., Danik H.J., Dec Jr. G.W., et al. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J 151 (2006) 463-470
20. Lyden D.C., Olszewski J., Feran M., et al. Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 126 (1987) 432-438
21. Schwartz J., Sartini D., and Huber S. Myocarditis susceptibility in female mice depends upon ovarian cycle phase at infection. Virology 330 (2004) 16-23
22. Frisancho-Kiss S., Coronado M.J., Frisancho J.A., et al. Gonadectomy of male BALB/c mice increases Tim-3(+) alternatively activated M2 macrophages, Tim-3(+) T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun 23 (2009) 649-657
23. Cooper Jr. L.T., Berry G.J., and Shabetai R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators. N Engl J Med 336 (1997) 1860-1866
24. Fenoglio Jr. J.J., Ursell P.C., Kellogg C.F., et al. Diagnosis and classification of myocarditis by endomyocardial biopsy. N Engl J Med 308 (1983) 12-18
25. Kyto V., Saukko P., Lignitz E., et al. Diagnosis and presentation of fatal myocarditis. Hum Pathol 36 (2005) 1003-1007
26. Shen W.K., Edwards W.D., Hammill S.C., et al. Sudden unexpected nontraumatic death in 54 young adults: a 30-year population-based study. Am J Cardiol 76 (1995) 148-152
27. Passarino G., Burlo P., Ciccone G., et al. Prevalence of myocarditis at autopsy in Turin. Italy. Arch Pathol Lab Med 121 (1997) 619-622
28. Eckart R.E., Scoville S.L., Campbell C.L., et al. Sudden death in young adults: a 25-year review of autopsies in military recruits. Ann Intern Med 141 (2004) 829-834
29. Maron B.J., Doerer J.J., Haas T.S., et al. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation 119 (2009) 1085-1092
30. Rasten-Almqvist P., Eksborg S., and Rajs J. Myocarditis and sudden infant death syndrome. Apmis 110 (2002) 469-480
31. Topaz O., and Edwards J.E. Pathologic features of sudden death in children, adolescents, and young adults. Chest 87 (1985) 476-482
32. Neuspiel D.R., and Kuller L.H. Sudden and unexpected natural death in childhood and adolescence. JAMA 254 (1985) 1321-1325
33. Nugent A.W., Daubeney P.E., Chondros P., et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 348 (2003) 1639-1646
34. Weber M.A., Ashworth M.T., Risdon R.A., et al. Clinicopathological features of paediatric deaths due to myocarditis: an autopsy series. Arch Dis Child 93 (2008) 594-598
35. Towbin J.A., Lowe A.M., Colan S.D., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296 (2006) 1867-1876
36. Rahman J.E., Helou E.F., Gelzer-Bell R., et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43 (2004) 410-415
37. Frustaci A., Verardo R., Caldarulo M., et al. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J 28 (2007) 733-740
38. Pieroni M., Dello Russo A., Marzo F., et al. High prevalence of myocarditis mimicking arrhythmogenic right ventricular cardiomyopathy differential diagnosis by electroanatomic mapping-guided endomyocardial biopsy. J Am Coll Cardiol 53 (2009) 681-689
39. Basso C., Corrado D., Marcus F.I., et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet 373 (2009) 1289-1300
40. McCully R.B., Cooper L.T., and Schreiter S. Coronary artery spasm in lymphocytic myocarditis: a rare cause of acute myocardial infarction. Heart (British Cardiac Society) 91 (2005) 202
41. Hufnagel G., Pankuweit S., Richter A., et al. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID). First epidemiological results. Herz 25 (2000) 279-285
42. Freedman S.B., Haladyn J.K., Floh A., et al. Pediatric myocarditis: emergency department clinical findings and diagnostic evaluation. Pediatrics 120 (2007) 1278-1285
43. Amabile N., Fraisse A., Bouvenot J., et al. Outcome of acute fulminant myocarditis in children. Heart (British Cardiac Society) 92 (2006) 1269-1273
44. Morgera T., Di Lenarda A., Dreas L., et al. Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J 124 (1992) 455-467
45. Vignola P.A., Aonuma K., Swaye P.S., et al. Lymphocytic myocarditis presenting as unexplained ventricular arrhythmias: diagnosis with endomyocardial biopsy and response to immunosuppression. J Am Coll Cardiol 4 (1984) 812-819
46. Dec Jr. G.W., Waldman H., Southern J., et al. Viral myocarditis mimicking acute myocardial infarction. J Am Coll Cardiol 20 (1992) 85-89
47. Kuhl U., Pauschinger M., Seeberg B., et al. Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation 112 (2005) 1965-1970
48. Nakashima H., Katayama T., Ishizaki M., et al. Q wave and non-Q wave myocarditis with special reference to clinical significance. Jpn Heart J 39 (1998) 763-774
49. Greenwood R.D., Nadas A.S., and Fyler D.C. The clinical course of primary myocardial disease in infants and children. Am Heart J 92 (1976) 549-560
50. Fuse K., Kodama M., Okura Y., et al. Predictors of disease course in patients with acute myocarditis. Circulation 102 (2000) 2829-2835
51. Nishii M., Inomata T., Takehana H., et al. Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 44 (2004) 1292-1297
52. Smith S.C., Ladenson J.H., Mason J.W., et al. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 95 (1997) 163-168
53. Franz W.M., Remppis A., Kandolf R., et al. Serum troponin T: diagnostic marker for acute myocarditis. Clin Chem 42 (1996) 340-341
54. Lauer B., Niederau C., Kuhl U., et al. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 30 (1997) 1354-1359
55. Soongswang J., Durongpisitkul K., Nana A., et al. Cardiac troponin T: a marker in the diagnosis of acute myocarditis in children. Pediatr Cardiol 26 (2005) 45-49
56. Pinamonti B., Alberti E., Cigalotto A., et al. Echocardiographic findings in myocarditis. Am J Cardiol 62 (1988) 285-291
57. Nieminen M.S., Heikkila J., and Karjalainen J. Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings. Am J Cardiol 53 (1984) 1331-1337
58. Mendes L.A., Dec G.W., Picard M.H., et al. Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis. Am Heart J 128 (1994) 301-307
59. Angelini A., Calzolari V., Calabrese F., et al. Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart (British Cardiac Society) 84 (2000) 245-250
60. James K.B., Lee K., Thomas J.D., et al. Left ventricular diastolic dysfunction in lymphocytic myocarditis as assessed by Doppler echocardiography. Am J Cardiol 73 (1994) 282-285
61. Daly K., Monaghan M., Richardson P., et al. Significant incidence of mural thrombi in acute myocarditis-indications for early anticoagulation (abstract). J Am Coll Cardiol 1 (1983) 584
62. Felker G.M., Boehmer J.P., Hruban R.H., et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36 (2000) 227-232
63. Friedrich M.G., Strohm O., Schulz-Menger J., et al. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation 97 (1998) 1802-1809
64. Laissy J.P., Messin B., Varenne O., et al. MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest 122 (2002) 1638-1648
65. Laissy J.P., Hyafil F., Feldman L.J., et al. Differentiating acute myocardial infarction from myocarditis: diagnostic value of early- and delayed-perfusion cardiac MR imaging. Radiology 237 (2005) 75-82
66. Abdel-Aty H., Boye P., Zagrosek A., et al. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol 45 (2005) 1815-1822
67. Mahrholdt H., Wagner A., Deluigi C.C., et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation 114 (2006) 1581-1590
68. Yilmaz A., Mahrholdt H., Athanasiadis A., et al. Coronary vasospasm as the underlying cause for chest pain in patients with PVB19 myocarditis. Heart (British Cardiac Society) 94 (2008) 1456-1463
69. Asimaki A., Tandri H., Huang H., et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 360 (2009) 1075-1084
70. Holzmann M., Nicko A., Kuhl U., et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 118 (2008) 1722-1728
71. Matsumori A., Shimada T., Chapman N.M., et al. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail 12 (2006) 293-298
72. Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 96 (2005) 144-147
73. Herskowitz A., Wu T.C., Willoughby S.B., et al. Myocarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. J Am Coll Cardiol 24 (1994) 1025-1032
74. Breuckmann F., Neumann T., Kondratieva J., et al. Dilated cardiomyopathy in two adult human immunodeficiency positive (HIV+) patients possibly related to highly active antiretroviral therapy (HAART). Eur J Med Res 10 (2005) 395-399
75. Chen F., Shannon K., Ding S., et al. HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Res Hum Retrovir 18 (2002) 777-784
76. Lanjewar D.N., Katdare G.A., Jain P.P., et al. Pathology of the heart in acquired immunodeficiency syndrome. Indian Heart J 50 (1998) 321-325
77. Hofman P., Drici M.D., Gibelin P., et al. Prevalence of toxoplasma myocarditis in patients with the acquired immunodeficiency syndrome. Br Heart J 70 (1993) 376-381
78. Pugliese A., Isnardi D., Saini A., et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 40 (2000) 282-284
79. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets 5 (2005) 337-343
80. Costello J.M., Alexander M.E., Greco K.M., et al. Lyme carditis in children: presentation, predictive factors, and clinical course. Pediatrics 123 (2009) e835-e841
81. Stanek G., Klein J., Bittner R., et al. Borrelia burgdorferi as an etiologic agent in chronic heart failure. Scand J Infect Dis 77 (1991) 85-87
82. + T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 56 (1997) 485-489
83. Acquatella H. Echocardiography in Chagas heart disease. Circulation 115 (2007) 1124-1131
84. Maguire J.H., Hoff R., Sherlock I., et al. Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation 75 (1987) 1140-1145
85. Simmons A., Vacek J.L., and Meyers D. Anthracycline-induced cardiomyopathy. Postgraduate medicine 120 (2008) 67-72
86. Phillips K., Luk A., Soor G.S., et al. Cocaine cardiotoxicity: a review of the pathophysiology, pathology, and treatment options. Am J Cardiovasc Drugs 9 (2009) 177-196
87. Taliercio C.P., Olney B.A., and Lie J.T. Myocarditis related to drug hypersensitivity. Mayo Clin Proc 60 (1985) 463-468
88. Hervier B., Masseau A., Bossard C., et al. Vasa-vasoritis of the aorta and fatal myocarditis in fulminant Churg-Strauss syndrome. Rheumatology (Oxford) 47 (2008) 1728-1729
89. Frustaci A., Cuoco L., Chimenti C., et al. Celiac disease associated with autoimmune myocarditis. Circulation 105 (2002) 2611-2618
90. Corssmit E.P., Trip M.D., and Durrer J.D. Loffler's endomyocarditis in the idiopathic hypereosinophilic syndrome. Cardiology 91 (1999) 272-276
91. Kirchhoff L.V., Weiss L.M., Wittner M., et al. Parasitic diseases of the heart. Front Biosci 9 (2004) 706-723
92. Dilber E., Karagoz T., Aytemir K., et al. Acute myocarditis associated with tetanus vaccination. Mayo Clin Proc 78 (2003) 1431-1433
93. Cassimatis D.C., Atwood J.E., Engler R.M., et al. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 43 (2004) 1503-1510
94. Davies M.J., Pomerance A., and Teare R.D. Idiopathic giant cell myocarditis-a distinctive clinico-pathological entity. Br Heart J 37 (1975) 192-195
95. Kilgallen C.M., Jackson E., Bankoff M., et al. A case of giant cell myocarditis and malignant thymoma: a postmortem diagnosis by needle biopsy. Clin Cardiol 21 (1998) 48-51
96. Daniels P.R., Berry G.J., Tazelaar H.D., et al. Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol 9 (2000) 287-291
97. Litovsky S.H., Burke A.P., and Virmani R. Giant cell myocarditis: an entity distinct from sarcoidosis characterized by multiphasic myocyte destruction by cytotoxic T cells and histiocytic giant cells. Mod Pathol 9 (1996) 1126-1134
98. Okura Y., Dec G.W., Hare J.M., et al. A clinical and histopathologic comparison of cardiac sarcoidosis and idiopathic giant cell myocarditis. J Am Coll Cardiol 41 (2003) 322-329
99. Yazaki Y., Isobe M., Hiramitsu S., et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 82 (1998) 537-540
100. Badorff C., Lee G.H., Lamphear B.J., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5 (1999) 320-326
101. Lozano M.D., Rubocki R.J., Wilson J.E., et al. Human leukocyte antigen class II associations in patients with idiopathic dilated cardiomyopathy. Myocarditis Treatment Trial Investigators. J Card Fail 3 (1997) 97-103
102. Tchilian E.Z., Gil J., Navarro M.L., et al. Unusual case presentations associated with the CD45 C77G polymorphism. Clin Exp Immunol 146 (2006) 448-454
103. Beck M.A., Levander O.A., and Handy J. Selenium deficiency and viral infection. J Nutr 133 5 Suppl 1 (2003) 1463S-1467S
104. Ilback N.G., Wesslen L., Fohlman J., et al. Effects of methyl mercury on cytokines, inflammation and virus clearance in a common infection (coxsackie B3 myocarditis). Toxicol Lett 89 (1996) 19-28
105. Cooper L.T., Rader V., and Ralston N.V. The roles of selenium and mercury in the pathogenesis of viral cardiomyopathy. Congest Heart Fail (Greenwich, Conn) 13 (2007) 193-199
106. Tracy S., Hofling K., Pirruccello S., et al. Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice. Journal of medical virology 62 (2000) 70-81
107. Bergelson J.M., Cunningham J.A., Droguett G., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science (New York, NY) 275 (1997) 1320-1323
108. Shafren D.R., Bates R.C., Agrez M.V., et al. Coxsackieviruses B1, B3, and B5 use decay accelerating factor as a receptor for cell attachment. J Virol 69 (1995) 3873-3877
109. Wickham T.J., Filardo E.J., Cheresh D.A., et al. Integrin alpha v beta 5 selectively promotes adenovirus mediated cell membrane permeabilization. J Cell Biol 127 (1994) 257-264
110. Wickham T.J., Mathias P., Cheresh D.A., et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73 (1993) 309-319
111. Salone B., Martina Y., Piersanti S., et al. Integrin alpha3beta1 is an alternative cellular receptor for adenovirus serotype 5. J Virol 77 (2003) 13448-13454
112. Martino T.A., Petric M., Brown M., et al. Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 244 (1998) 302-314
113. Fechner H., Noutsias M., Tschoepe C., et al. Induction of coxsackievirus-adenovirus-receptor expression during myocardial tissue formation and remodeling: identification of a cell-to-cell contact-dependent regulatory mechanism. Circulation 107 (2003) 876-882
114. Kashimura T., Kodama M., Hotta Y., et al. Spatiotemporal changes of coxsackievirus and adenovirus receptor in rat hearts during postnatal development and in cultured cardiomyocytes of neonatal rat. Virchows Arch 444 (2004) 283-292
115. Shi Y., Chen C., Lisewski U., et al. Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J Am Coll Cardiol 53 (2009) 1219-1226
116. Huber S.A. Autoimmunity in coxsackievirus B3 induced myocarditis. Autoimmunity 39 (2006) 55-61
117. Huang C.H., Vallejo J.G., Kollias G., et al. Role of the innate immune system in acute viral myocarditis. Basic Res Cardiol 104 (2009) 228-237
118. Lowenstein C.J., Hill S.L., Lafond-Walker A., et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 97 (1996) 1837-1843
119. Szalay G., Sauter M., Hald J., et al. Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders. Am J Pathol 169 (2006) 2085-2093
120. Hardarson H.S., Baker J.S., Yang Z., et al. Toll-like receptor 3 is an essential component of the innate stress response in virus-induced cardiac injury. Am J Physiol 292 (2007) H251-H258
121. Fuse K., Chan G., Liu Y., et al. Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112 (2005) 2276-2285
122. Fairweather D., Frisancho-Kiss S., Njoku D.B., et al. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J Immunol 176 (2006) 3516-3524
123. Chow L.H., Beisel K.W., and McManus B.M. Enteroviral infection of mice with severe combined immunodeficiency. Evidence for direct viral pathogenesis of myocardial injury. Lab Invest 66 (1992) 24-31
124. Lamphear B.J., Yan R., Yang F., et al. Mapping the cleavage site in protein synthesis initiation factor eIF-4 gamma of the 2A proteases from human Coxsackievirus and rhinovirus. J Biol Chem 268 (1993) 19200-19203
125. Xiong D., Yajima T., Lim B.K., et al. Inducible cardiac-restricted expression of enteroviral protease 2A is sufficient to induce dilated cardiomyopathy. Circulation 115 (2007) 94-102
126. Chau D.H., Yuan J., Zhang H., et al. Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. Apoptosis 12 (2007) 513-524
127. Pummerer C., Berger P., Fruhwirth M., et al. Cellular infiltrate, major histocompatibility antigen expression and immunopathogenic mechanisms in cardiac myosin-induced myocarditis. Lab Invest 65 (1991) 538-547
128. Goser S., Ottl R., Brodner A., et al. Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112 (2005) 3400-3407
129. Rangachari M., Mauermann N., Marty R.R., et al. T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med 203 (2006) 2009-2019
130. Haga T., Suzuki J., Kosuge H., et al. Attenuation of experimental autoimmune myocarditis by blocking T cell activation through 4-1BB pathway. J Mol Cell Cardiol 46 (2009) 719-727
131. Afanasyeva M., Wang Y., Kaya Z., et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Autoimmunity 159 (2001) 193-203
132. Eriksson U., Ricci R., Hunziker L., et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9 (2003) 1484-1490
133. Hayward S.L., Bautista-Lopez N., Suzuki K., et al. CD4 T cells play major effector role and CD8 T cells initiating role in spontaneous autoimmune myocarditis of HLA-DQ8 transgenic IAb knockout nonobese diabetic mice. J Immunol 176 (2006) 7715-7725
134. Neumann D.A., Rose N.R., Ansari A.A., et al. Induction of multiple heart autoantibodies in mice with coxsackievirus B3- and cardiac myosin-induced autoimmune myocarditis. J Immunol 152 (1994) 343-350
135. Caforio A.L., Mahon N.J., Tona F., et al. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 4 (2002) 411-417
136. Neumann D.A., Burek C.L., Baughman K.L., et al. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol 16 (1990) 839-846
137. Caforio A.L., Mahon N.J., and McKenna W.J. Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy. Autoimmunity 34 (2001) 199-204
138. Wallukat G., Morwinski M., Kowal K., et al. Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitization. Eur Heart J 12 Suppl D (1991) 178-181
139. Staudt A., Dorr M., Staudt Y., et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 150 (2005) 729-736
140. Warraich R.S., Noutsias M., Kazak I., et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J 143 (2002) 1076-1084
141. Latva-Hirvela J., Kyto V., Saraste A., et al. Development of troponin autoantibodies in experimental coxsackievirus B3 myocarditis. Eur J Clin Invest 39 (2009) 457-462
142. Kaya Z., Katus H.A., and Rose N.R. Cardiac troponins and autoimmunity: Their role in the pathogenesis of myocarditis and of heart failure. Clin Immunol (Orlando, Fla) (2009)
143. Goser S., Andrassy M., Buss S.J., et al. Cardiac troponin I but not cardiac troponin T induces severe autoimmune inflammation in the myocardium. Circulation 114 (2006) 1693-1702
144. Matsumori A., Igata H., Ono K., et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. Jpn Circ J 63 (1999) 934-940
145. Wang W.Z., Matsumori A., Yamada T., et al. Beneficial effects of amlodipine in a murine model of Congest Heart Fail induced by viral myocarditis. A possible mechanism through inhibition of nitric oxide production. Circulation 95 (1997) 245-251
146. Liu W., Shimada M., Xiao J., et al. Nifedipine inhibits the activation of inflammatory and immune reactions in viral myocarditis. Life Sci 85 (2009) 235-240
147. Khatib R., Reyes M.P., and Smith F.E. Enhancement of Coxsackievirus B3 replication in Vero cells by indomethacin. J Infect Dis 162 (1990) 997-998
148. Khatib R., Reyes M.P., Smith F., et al. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Clin Med 116 (1990) 116-120
149. Costanzo-Nordin M.R., Reap E.A., O'Connell J.B., et al. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol 6 (1985) 1078-1082
150. Pages O.N., Aubert S., Combes A., et al. Paracorporeal pulsatile biventricular assist device versus extracorporal membrane oxygenation-extracorporal life support in adult fulminant myocarditis. J Thorac Cardiovasc Surg 137 (2009) 194-197
151. Duncan B.W., Bohn D.J., Atz A.M., et al. Mechanical circulatory support for the treatment of children with acute fulminant myocarditis. J Thorac Cardiovasc Surg 122 (2001) 440-448
152. Reinhartz O., Hill J.D., Al-Khaldi A., et al. Thoratec ventricular assist devices in pediatric patients: update on clinical results. Asaio J 51 (2005) 501-503
153. Topkara V.K., Dang N.C., Barili F., et al. Ventricular assist device use for the treatment of acute viral myocarditis. J Thorac Cardiovasc Surg 131 (2006) 1190-1191
154. Bowles N.E., Ni J., Kearney D.L., et al. Detection of viruses in myocardial tissues by polymerase chain reaction. evidence of adenovirus as a common cause of myocarditis in children and adults. J Am Coll Cardiol 42 (2003) 466-472
155. Wang Y.X., da Cunha V., Vincelette J., et al. Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice. Am J Physiol 293 (2007) H69-H76
156. Horwitz M.S., La Cava A., Fine C., et al. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat Med 6 (2000) 693-697
157. Okada I., Matsumori A., Matoba Y., et al. Combination treatment with ribavirin and interferon for coxsackievirus B3 replication. J Lab Clin Med 120 (1992) 569-573
158. Matsumori A., Crumpacker C.S., and Abelmann W.H. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model. J Am Coll Cardiol 9 (1987) 1320-1325
159. Ray C.G., Icenogle T.B., Minnich L.L., et al. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis 159 (1989) 829-836
160. Kuhl U., Pauschinger M., Schwimmbeck P.L., et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 107 (2003) 2793-2798
161. Jones S.R., Herskowitz A., Hutchins G.M., et al. Effects of immunosuppressive therapy in biopsy-proved myocarditis and borderline myocarditis on left ventricular function. Am J Cardiol 68 (1991) 370-376
162. Maisch B., Camerini F., and Schultheiss H.P. Immunosuppressive therapy for myocarditis. N Engl J Med 333 (1995) 1713 [author reply 4]
163. McNamara D.M., Rosenblum W.D., Janosko K.M., et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 95 (1997) 2476-2478
164. McNamara D.M., Starling R.C., and Dec G.W. Intervention in myocarditis and acute cardiomyopathy with immune globulin: results from the randomized placebo controlled IMAC trial. Circulation 100 Suppl I (1999) I-21 [Abstract]
165. Cooper Jr. L.T., Hare J.M., Tazelaar H.D., et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 102 (2008) 1535-1539
166. Chan K.Y., Iwahara M., Benson L.N., et al. Immunosuppressive therapy in the management of acute myocarditis in children: a clinical trial. J Am Coll Cardiol 17 (1991) 458-460
167. Drucker N.A., Colan S.D., Lewis A.B., et al. Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89 (1994) 252-257
168. Parrillo J.E., Cunnion R.E., Epstein S.E., et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 321 (1989) 1061-1068
169. Wojnicz R., Nowalany-Kozielska E., Wojciechowska C., et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 104 (2001) 39-45
170. Frustaci A., Chimenti C., Calabrese F., et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 107 (2003) 857-863
171. Gullestad L., Aass H., Fjeld J.G., et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 103 (2001) 220-225
172. Frustaci A., Russo M.A., and Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J (2009)
173. Camargo P.R., Snitcowsky R., da Luz P.L., et al. Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol 16 (1995) 61-68
174. Balaji S., Wiles H.B., Sens M.A., et al. Immunosuppressive treatment for myocarditis and borderline myocarditis in children with ventricular ectopic rhythm. Br Heart J 72 (1994) 354-359
175. McNamara D.M., Holubkov R., Starling R.C., et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 103 (2001) 2254-2259
176. Cabinian A.E., Kiel R.J., Smith F., et al. Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model. J Lab Clin Med 115 (1990) 454-462
177. Maron B.J. Sudden death in young athletes. N Engl J Med 349 (2003) 1064-1075
178. Maron B.J., Ackerman M.J., Nishimura R.A., et al. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol 45 (2005) 1340-1345
179. Magnani J.W., and Dec G.W. Myocarditis: current trends in diagnosis and treatment. Circulation 113 (2006) 876-890
180. McCarthy III R.E., Boehmer J.P., Hruban R.H., et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 (2000) 690-695
181. Sheppard R., Bedi M., Kubota T., et al. Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol 46 (2005) 1036-1042
182. Fuse K., Kodama M., Okura Y., et al. Short-term prognostic value of initial serum levels of interleukin-10 in patients with acute myocarditis. Eur J Heart Fail 7 (2005) 109-112
183. Gagliardi M.G., Bevilacqua M., Bassano C., et al. Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart (British Cardiac Society) 90 (2004) 1167-1171
184. Cooper D.K., Schlesinger R.G., Shrago S., et al. Heart transplantation for giant cell myocarditis. J Heart Lung Transplant 13 (1994) 555
185. Singh T.P., Rabah R., Cooper L.T., et al. Total lymphoid irradiation: new therapeutic option for refractory giant cell myocarditis. J Heart Lung Transplant 23 (2004) 492-495
186. Fontanella G.H., De Vusser K., Laroy W., et al. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate. Vaccine 26 (2008) 2322-2334
187. Fohlman J., Ilback N.G., Friman G., et al. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 8 (1990) 381-384
188. Oberg A.L., Mahoney D.W., Eckel-Passow J.E., et al. Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. J Proteome Res 7 (2008) 225-233